Topical pimecrolimus in the treatment of human allergic contact dermatitis

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 6, 2003, Pages 563-566

  Amrol, David ^a,b   Keitel, Duane ^a   Hagaman, David ^a   Murray, John ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUATE DRY SKIN CREAM; LACTAM; PIMECROLIMUS; PLACEBO;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; POISON IVY; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RASH; SCORING SYSTEM; SKIN ALLERGY; TOPICAL TREATMENT;

EID: 0346362485     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61535-9     Document Type: Article

References (16)

1. Rietschel R. Human and economic impact of allergic contact dermatitis and the role of patch testing. J Am Acad Dermatol. 1995;33:812-815.
2. Middleton E, Reed CE, Ellis EF, et al, editors. Allergy: Principles and Practice. Fifth ed. St. Louis, MO: Mosby-Yearbook; 1998:1135-1147.
3. Baer RL. Poison ivy dermatitis. Cutis. 1990;46:34-36.
4. Paller A. Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. J Pediatr. 2001;138:163-168.
5. Grassberger M, Baumruker T, Enz A, et al. A novel antiinflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264-273.
6. Eichenfield L, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
7. Furue M, Osada A, Chang CH, Tamaki K. Immunosuppressive effects of azelastine hydrochloride on contact hypersensitivity and T-cell proliferative response: a comparative study with FK-506. J Invest Dermatol. 1994;103:49-53.
8. Salerno A, Bonanno CT, Caccamo N, et al. The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. Clin Exp Immunol. 1998;112:112-119.
9. Lauerma A, Stein B, Homey B, Lee CH, Bloom E, Maibach HI. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res. 1994;286:337-340.
10. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol. 1992;98:851-855.
11. Cherill R, Toft S, MacNaul R, et al. 1% SDZ ASM 981 cream effective in the treatment of chronic irritant hand dermatitis: a 6-week, randomized, double-blind, vehicle-controlled, single-center study. J Eur Dermatol Venereol. 2000;14(Suppl):128.
12. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet. 1992;340:556.
13. Beltrani VS, Beltrani VP. Contact dermatitis. Ann Allergy Asthma Immunol. 1997;78:160-176.
14. Hebert AA, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg. 2001;20:260-267.
15. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160.
16. 2). Ann Allergy Asthma Immunol. 2000;85:9-18, 21.